Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q3 2022 call → NOWe need to determine if the company is currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event at the end. The transcript discusses clinical trials, pipeline development, and financing. The company is spending on R&D for CUE-101 and CUE-102, but these are ongoing trials. The management talks about upcoming milestones: mature median overall survival data by end of this year, preliminary ORR in Q2 next year, etc. But are they paying for something not yet earning? The trials are ongoing, but the company is a biotech with no product revenue. The costs are R&D expenses. The waiting period is the clinical development before approval. However, the question asks if management describes the company as currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event. The events are data readouts, not necessarily a crossing that changes earning capability. The company is not yet earning from the product. But the essence is: is there a specific near-dated event that ends the wait, and is the company paying for it now? The management does mention milestones like "mature median overall survival data by the end of this year" and "preliminary overall response rate in the second quarter of next year." These are data readouts, not necessarily a start of revenue. The company is still in clinical trials. The costs are R&D, which are ordinary for a biotech. The question asks if the company is paying for something not yet earning, and the end is a specific event. But the event is a data readout, not a commercial launch. The company is not yet earning from the product. However, the question says "the company is presently carrying real, ongoing cash or earnings cost for something whose benefit has not arrived yet" - that could be the clinical trials. But the benefit is not necessarily a near-dated event that changes earning capability. The management does not describe a waiting period where they are paying for a facility or something that will start earning. They are just running trials. The essence is a company bearing the cost of a gap it has chosen to stand in, with the far edge already dated and already largely paid for. The far edge is a data readout, not a revenue-generating event.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.